Everolimus Treatment in a Neonate with Heart Failure Caused by Cardiac Rhabdomyomas

Abstract

Most primary pediatric cardiac tumors are rhabdomyomas, which are generally associated with tuberous sclerosis complex. Large tumors can sometimes cause heart failure, and surgery might be required for patient survival. Everolimus, an oral mammalian target of rapamycin inhibitor, has been recently studied for its antineoplastic effect. Here, we describe a case involving successful everolimus treatment for cardiac rhabdomyomas in a neonate.